Blueprint Medicines is a global biopharmaceutical company dedicated to inventing life-changing medicines, focusing on allergy/inflammation and oncology/hematology. Their approach combines deep scientific expertise with modality-agnostic drug discovery capabilities, leading to a proven track record of research and development success.

Blueprint Medicines is advancing a diverse pipeline of investigational therapies targeting mast cell disorders and various cancers. Their research focuses on areas where they are uniquely positioned to drive scientific leadership, pioneer treatment innovation, and improve patient outcomes. They have expanded their scientific platform beyond kinase inhibitors to include additional modalities, such as targeted protein degradation, and have incorporated state-of-the-art translational medicine capabilities and new technologies, including artificial intelligence and machine learning tools, to enhance the productivity and efficiency of their drug discovery efforts.

Blueprint Medicines achieves impactful results because of their global crew of compassionate innovators – the Blue Crew. Through authentic relationships and  collective entrepreneurial spirit and action, they are each empowered to take ownership and execute with strategic prioritization. They put trust in their people to break through norms and conventions using their individual strengths and insights, which drives Blueprint’s success.